Xiaoyou Li
Overview
Explore the profile of Xiaoyou Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
347
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li S, Li X, Xu H, Huang J, Zhu J, Peng Y, et al.
Signal Transduct Target Ther
. 2024 Dec;
9(1):346.
PMID: 39658608
Previous studies showed encouraging efficacy of alternating FOLFOX/FOLFIRI for metastatic colorectal cancer (mCRC). This phase 2 trial (NCT04324476) aimed to evaluate efficacy and safety of alternating modified CAPOX (capecitabine and...
2.
Zhang M, Wang L, Wang Q, Yang J, Peng W, Li X, et al.
Front Oncol
. 2024 Nov;
14:1441025.
PMID: 39568568
Background: Non-small cell lung cancer (NSCLC) with human epidermal growth factor receptor 2 () alterations poses a substantial treatment challenge. Current -targeted therapies offer limited efficacy. Antibody-drug conjugates (ADCs) targeting...
3.
Li S, Li X, Zhu Q, Gao J, Zhu C, Zhu L
Cancer Control
. 2024 Sep;
31:10732748241275012.
PMID: 39286935
Objectives: Clinical studies have shown that bevacizumab plus chemotherapy significantly improves efficacy in metastatic colorectal cancer (mCRC). This prospective study aims to investigate the efficacy and safety of changing second-line...
4.
Sui Y, Shen Z, Li X, Lu Y, Feng S, Ma R, et al.
Cell Death Dis
. 2024 Aug;
15(8):561.
PMID: 39097608
The obstacle to effectively treating Diffuse Large B-cell Lymphoma (DLBCL) lies in the resistance observed toward standard therapies. Identifying therapeutic targets that prove effective for relapsed or refractory patients poses...
5.
Yan F, Teng Y, Li X, Zhong Y, Li C, Yan F, et al.
Cancer Biol Ther
. 2024 Jan;
25(1):2304161.
PMID: 38226837
Background: Lung cancer is the deadliest form of malignancy and the most common subtype is non-small cell lung cancer (NSCLC). Hypoxia is a typical feature of solid tumor microenvironment. In...
6.
Li S, Bao J, Li X, Yang Q, Xu J, Chen S, et al.
EClinicalMedicine
. 2023 Nov;
66:102314.
PMID: 38024480
Background: Pembrolizumab plus trastuzumab and chemotherapy showed remarkable efficacy as first-line therapy for advanced HER2-positive gastric cancer. Pyrotinib is an irreversible pan-HER inhibitor. This single-arm, open-label phase 1 dose-escalation (1a)...
7.
Guo Y, Liu S, Yan F, Yin N, Ni J, Li C, et al.
Front Oncol
. 2022 Dec;
12:927771.
PMID: 36505777
Introduction: Cognitive impairment has been identified in patients with non-central nervous system cancer received chemotherapy. Chemotherapy-induced changes in the brain are considered as the possible causes of the cognitive deficits...
8.
Liu S, Ni J, Yan F, Yin N, Li X, Ma R, et al.
Front Oncol
. 2022 Nov;
12:1027515.
PMID: 36408140
Introduction: Chemotherapy-induced cognitive impairment (CICI), termed "chemobrain", is highly prevalent in cancer patients following the administration of chemotherapeutic agents. However, the potential pathophysiological mechanisms underlying CICI remain unknown. This study...
9.
Qian S, Chen X, Jiang S, Sun Q, Chen X, Lu J, et al.
Opt Express
. 2022 Oct;
30(15):27322-27332.
PMID: 36236906
Compared with ex situ measurement, the in situ measurement is more suitable for inspecting complex electrochemical reactions and improving the intelligent energy storage management. However, most of the in situ...
10.
Liu S, Guo Y, Ni J, Yin N, Li C, Pan X, et al.
Front Oncol
. 2022 Aug;
12:900855.
PMID: 35924154
Introduction: Chemotherapy-induced cognitive impairment (i.e., "chemobrain") is a common neurotoxic side-effect experienced by many cancer survivors who undergone chemotherapy. However, the central mechanism underlying chemotherapy-related cognitive impairment is still unclear....